MCID: LPG001
MIFTS: 29

Lipogranulomatosis

Categories: Rare diseases

Aliases & Classifications for Lipogranulomatosis

MalaCards integrated aliases for Lipogranulomatosis:

Name: Lipogranulomatosis 52 54
Erdheim-Chester Disease 71
Lipogranuloma 71

Classifications:



External Ids:

UMLS 71 C0878675 C1704214

Summaries for Lipogranulomatosis

MalaCards based summary : Lipogranulomatosis, also known as erdheim-chester disease, is related to farber lipogranulomatosis and asah1-related disorders. An important gene associated with Lipogranulomatosis is ASAH1 (N-Acylsphingosine Amidohydrolase 1), and among its related pathways/superpathways are Sphingolipid metabolism and S-1P Stimulated Signaling. The drugs Diclofenac and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and liver.

Related Diseases for Lipogranulomatosis

Graphical network of the top 20 diseases related to Lipogranulomatosis:



Diseases related to Lipogranulomatosis

Symptoms & Phenotypes for Lipogranulomatosis

Drugs & Therapeutics for Lipogranulomatosis

Drugs for Lipogranulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 3 15307-86-5 3033
2 Anti-Inflammatory Agents Phase 3
3 Anti-Inflammatory Agents, Non-Steroidal Phase 3
4 Analgesics, Non-Narcotic Phase 3
5 Cyclooxygenase Inhibitors Phase 3
6 Antirheumatic Agents Phase 3
7 Analgesics Phase 3
8
Trametinib Approved Phase 2 871700-17-3 11707110
9
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
10
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
11
Lenalidomide Approved Phase 2 191732-72-6 216326
12 Mitogens Phase 2
13 Protein Kinase Inhibitors Phase 2
14 Free Radical Scavengers Phase 2
15 Antioxidants Phase 2
16 Protective Agents Phase 2
17 Angiogenesis Inhibitors Phase 2
18 Immunologic Factors Phase 2
19
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
20
Cetuximab Approved Phase 1 205923-56-4 56842117 2333
21
Everolimus Approved Phase 1 159351-69-6 6442177 70789204
22
Bevacizumab Approved, Investigational Phase 1 216974-75-3
23
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
24
Valproic acid Approved, Investigational Phase 1 99-66-1 3121
25 Antibodies, Monoclonal Phase 1
26 Antineoplastic Agents, Immunological Phase 1
27 Tranquilizing Agents Phase 1
28 Endothelial Growth Factors Phase 1
29 Neurotransmitter Agents Phase 1
30 Anti-Infective Agents Phase 1
31 GABA Agents Phase 1
32 Antibiotics, Antitubercular Phase 1
33 Antifungal Agents Phase 1
34 Psychotropic Drugs Phase 1
35 Anti-Bacterial Agents Phase 1
36 Immunoglobulins Phase 1
37 Antimanic Agents Phase 1
38 Central Nervous System Depressants Phase 1
39 Immunoglobulin G Phase 1
40 Anticonvulsants Phase 1
41 Immunosuppressive Agents Phase 1
42 Antibodies Phase 1
43
Vemurafenib Approved 918504-65-1 23252090 42611257
44
Choline Approved, Nutraceutical 62-49-7 305
45 Gastrointestinal Agents
46 Hypolipidemic Agents
47 Nootropic Agents
48 Antimetabolites
49 Lipid Regulating Agents

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Tubal Flushing Using Water Soluble Media for Unexplained Infertility: A Randomized Controlled Trial Unknown status NCT02433418 Phase 3 Diclofenac
2 A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Completed NCT02281760 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
3 A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600 Mutation Positive Lesions in Erdheim Chester Disease Recruiting NCT03794297 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
4 A Phase II Study of Lenalidomide for Adult Histiocyte Disorders Active, not recruiting NCT02523040 Phase 2 Lenalidomide
5 A First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients With Advanced Tumors Not yet recruiting NCT04198818 Phase 1, Phase 2 HH2710
6 A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders. Not yet recruiting NCT04079179 Phase 2 Cobimetinib
7 Open-label, Single-arm, Phase II, Prospective, Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease Terminated NCT01727206 Phase 2 Tocilizumab
8 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
9 Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease Unknown status NCT02089724
10 Pilot Study to Determine Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement Completed NCT02608619
11 Clinical and Pathophysiological Investigations Into Erdheim-Chester Disease Completed NCT01417520
12 Registry for Patients With Erdheim-Chester Disease Recruiting NCT03329274
13 A Study to Identify the Supportive Care Needs of Caregivers of Patients With Erdheim-Chester Disease and Other Histiocytic Diseases Recruiting NCT03990428
14 Biomarker for Farber Disease - An International, Multicenter, Epidemiological Protocol Recruiting NCT02298634
15 International Rare Histiocytic Disorders Registry (IRHDR) Recruiting NCT02285582
16 A Clinical, Structural, and Functional Neuroimaging Study of Cognition in Adults With Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Rosai-Dorfman Disease, and Other Histiocytoses Recruiting NCT03127709
17 Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease Active, not recruiting NCT03233841

Search NIH Clinical Center for Lipogranulomatosis

Genetic Tests for Lipogranulomatosis

Anatomical Context for Lipogranulomatosis

MalaCards organs/tissues related to Lipogranulomatosis:

40
Breast, Bone, Liver, Skin, Endothelial, Bone Marrow, Lung

Publications for Lipogranulomatosis

Articles related to Lipogranulomatosis:

(show top 50) (show all 358)
# Title Authors PMID Year
1
Overexpression and mass spectrometry analysis of mature human acid ceramidase. 54 61
18020949 2007
2
Acid ceramidase is a novel factor required for early embryo survival. 54 61
17264167 2007
3
[Farber disease [Farber lipogranulomatosis], acid ceramidase deficiency]. 54 61
9645089 1998
4
Periocular Lipogranuloma After Cryopreserved Fat Injection Into the Forehead. 61
30882505 2019
5
Serious complication as a result of lip augmentation with vitamin E. 61
30924223 2019
6
Anaesthetic management of a child with Farber's lipogranulomatosis posted for exploratory laparotomy. 61
31772410 2019
7
Optic Nerve Involvement in Farber Lipogranulomatosis: Expanding the Phenotypic Spectrum. 61
31022067 2019
8
Retroperitoneal lipogranuloma mimicking recurrence of renal cell carcinoma after laparoscopic partial nephrectomy. 61
31236327 2019
9
Sclerosing lipogranulomatosis-induced chronic hypercalcemia and acute pancreatitis. 61
31312708 2019
10
Amelioration of regulatory T cells by Lactobacillus delbrueckii and Lactobacillus rhamnosus in pristane-induced lupus mice model. 61
30370554 2019
11
Facial Sclerosing Lipogranuloma After Self-Injection of Homemade Tissue Filler: An Alarming New Practice. 61
30908364 2019
12
No pain no gain: tender nodules in a competitive bodybuilder. 61
30261570 2018
13
Ophthalmologic Complications Associated With Oculofacial Plastic and Esthetic Surgeries. 61
29554075 2018
14
Role of Lgals9 Deficiency in Attenuating Nephritis and Arthritis in BALB/c Mice in a Pristane-Induced Lupus Model. 61
29481735 2018
15
Sclerosing lipogranuloma presenting as movable masses induced by large doses of progesterone injection. 61
29239023 2018
16
In vivo study: Th1-Th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic Lactobacillus probiotics. 61
30078223 2018
17
Paraffin Granuloma Associated with Buried Glans Penis-Induced Sexual and Voiding Dysfunction. 61
28868821 2017
18
Lipogranuloma after facial cosmetic procedures. 61
28117206 2017
19
Idiopathic orbital lipogranuloma. 61
28393047 2017
20
Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy. 61
27155573 2016
21
Subcutaneous Oleomas Following Sunflower Oil Injection: A Novel Case and Review of Literature. 61
28331751 2016
22
Periorbital Lipogranuloma after Autologous Fat Injection for Forehead Augmentation. 61
27081275 2016
23
Periorbital Lipogranuloma after Facial Autologous Fat Injection and Its Treatment Outcomes. 61
26865798 2016
24
Sclerosing Lipogranuloma with Multiple Skin Lesions and Pulmonary Involvement, Secondary to a Factitious Disorder. 61
26315839 2016
25
Silicone-induced Penile Sclerosing Lipogranuloma: Magnetic Resonance Imaging Findings. 61
26958433 2016
26
Periorbital Lipogranuloma Following Facial Autologous Fat Injections: Non-surgical Treatment. 61
26306704 2015
27
Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy. 61
26526000 2015
28
Clinical characteristics of patients with a periorbital mass after autologous fat injection for facial augmentation and short-term outcomes of steroid treatment. 61
26328476 2015
29
The molecular medicine of acid ceramidase. 61
25938220 2015
30
Extensive facial sclerosing lipogranulomatosis as a complication of cosmetic acupuncture. 61
25768878 2015
31
Complications of injected vitamin E as a filler for lip augmentation: case series and therapeutic approach. 61
25649466 2015
32
Sclerosing lipogranuloma of the eyelid: unusual complication following nasal packing in endoscopic sinus surgery. 61
25750223 2015
33
Primary adenomatoid tumor of the testis: report of a case and review of literature. 61
26191318 2015
34
Mesenteric lipogranuloma mimicking malignancy at ¹⁸F-FDG PET/CT in a patient with colon cancer. 61
24986550 2015
35
Molecular analyses of novel ASAH1 mutations causing Farber lipogranulomatosis: analyses of exonic splicing enhancer inactivating mutation. 61
24355074 2014
36
Treatment of paraffin-induced lipogranuloma of the penis by bipedicled scrotal flap with Y-V incision. 61
24322635 2014
37
[Case of primary scrotal sclerosing lipogranuloma : review of 227 cases reported in Japan]. 61
25511949 2014
38
Coelomic Granulomatous Fat Necrosis (Lipogranulomatosis) in an Umbrella Cockatoo (Cacatua alba). 61
25843325 2014
39
Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site. 61
24366197 2014
40
Periorbital lipogranuloma related to filler migration: a rare complication of facial fillers. 61
24131096 2014
41
A woman with a nose like an "Elephant's Trunk". 61
24245997 2014
42
Delayed lipogranuloma of the cheek following autologous fat injection: report of 2 cases. 61
25337297 2014
43
A giant primary sclerosing lipogranuloma of the scrotum. 61
24448708 2014
44
Periorbital lipogranuloma after cryopreserved autologous fat injection at forehead: unexpected complication of a popular cosmetic procedure. 61
24314435 2013
45
Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis. 61
23385296 2013
46
Lipogranulomatosis and hypersplenism induced by ruptured silicone breast implants. 61
24228267 2013
47
[Sonographic features and diagnostic analysis of breast granulomatous diseases: a report of 32 cases]. 61
24351602 2013
48
Comparative effects of different sclerosing agents used to treat rectal prolapse: an experimental study in rats. 61
23932615 2013
49
Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene. 61
23707712 2013
50
Eyelid-associated complications after autogenous fat injection for cosmetic forehead augmentation. 61
23841959 2013

Variations for Lipogranulomatosis

Expression for Lipogranulomatosis

Search GEO for disease gene expression data for Lipogranulomatosis.

Pathways for Lipogranulomatosis

Pathways related to Lipogranulomatosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.66 ASAH2 ASAH1
2 11.14 ASAH2 ASAH1
3 11.03 ASAH2 ASAH1
4 9.58 ASAH2 ASAH1

GO Terms for Lipogranulomatosis

Biological processes related to Lipogranulomatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.32 ASAH2 ASAH1
2 sphingolipid metabolic process GO:0006665 9.26 ASAH2 ASAH1
3 ceramide biosynthetic process GO:0046513 9.16 ASAH2 ASAH1
4 sphingosine biosynthetic process GO:0046512 8.96 ASAH2 ASAH1
5 ceramide catabolic process GO:0046514 8.62 ASAH2 ASAH1

Molecular functions related to Lipogranulomatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 N-acylsphingosine amidohydrolase activity GO:0017040 8.96 ASAH2 ASAH1
2 ceramidase activity GO:0102121 8.62 ASAH2 ASAH1

Sources for Lipogranulomatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....